Vicarious Surgical, Inc. · OTC:RBOT
Vicarious Surgical — SPAC Merger (April 2021)
32 slides from Vicarious Surgical's SPAC merger presentation, April 2021
Slide 1: Investor Presentation April 2021
INVESTOR PRESENTATION APRIL 2021 VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL
Slide 2: Disclaimer
DISCLAIMER This presentation is being furnished solely for the purpose of considering a potential transaction business combination disrupts Vicarious’ current plans and operations and potential difficulties in This document is being distributed solely for the consideration of sophisticated prospecti
Slide 3: Today's Presenters
TODAY’S PRESENTERS HOLDINGS CORP. CO-FOUNDER AND PRESIDENT CO-FOUNDER AND CEO EXECUTIVE CHAIRMAN CHIEF FINANCIAL OFFICER DONALD TANG ADAM SACHS DAVID STYKA BILL KELLY VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 00 | SUMMARY PRIVATE AND CONFIDENTIAL 3
Slide 4: Transaction Summary
TRANSACTION SUMMARY Vicarious is preparing to go public through a TRANSACTION STRUCTURE VALUATION business combination with D8 and is raising • Vicarious and D8 announced a • $1.1 billion post-money enterprise $115 million1 through a PIPE definitive business combination value; 3.1x 2025E revenue mul
Slide 5: Key Investment Highlights
KEY INVESTMENT HIGHLIGHTS NEXT GENER ATION ROBOTICS ABILITY TO ADDRESS MOST TECHNOLOGY ABDOMINAL PROCEDURES DESIGNED TO SOLVE MANUAL DEVELOPED IN STEALTH BY AND ROBOT-ASSISTED VISIONARY MANAGEMENT TEAM SURGERY SHORTCOMINGS AND INVESTORS TAPPING INTO A $136B ONLY ROBOT WITH FDA MARKET; 96.8% UNADDRES
Slide 6: Our Team and Investors
01 OUR TEAM AND INVESTORS VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL 6
Slide 7: Visionary Management Team
VISIONARY MANAGEMENT TEAM CHIEF FINANCIAL OFFICER GENERAL COUNSEL AND CHIEF LEGAL OFFICER BILL KELLY JUNE MORRIS CO-FOUNDER, CHIEF VP OF SOFTWARE VP OF SYSTEMS MEDICAL OFFICER NEERAJ MAINKAR DAVE WILKINSON BARRY GREENE CO-FOUNDER AND CEO CO-FOUNDER AND CTO EXECUTIVE CHAIRMAN ADAM SACHS SAMMY KHALIFA
Slide 8: Experienced Board and Advisors, Seasoned Investors
EXPERIENCED BOARD SEASONED AND ADVISORS INVESTORS SELECT EXISTING INVESTORS EXECUTIVE CHAIRMAN D8 BOARD DIRECTOR1 BOARD DIRECTOR BOARD DIRECTOR BOARD DIRECTOR DAVID STYKA DAVID HO PHIL LIANG ADAM SACHS RIC FULOP Bill Gates Noted HIV/AIDS Former Operational Researcher; Time “Man of Leader at Auris t
Slide 9: The Problem
02 THE PROBLEM VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL 9
Slide 10: The State of Surgery Today
THE STATE OF SURGERY TODAY TROCAR SIZE VICARIOUS SURGICAL EXISTING SINGLE ROBOTS 4 1.5CM 2.5CM PORT ROBOTS THE BEGINNING ONE STEP FORWARD ONE STEP BACKWARD STUCK AT THE BEGINNING OPEN MINIMALLY- EXISTING OPEN SURGERY INVASIVE SINGLE-PORT SURGERY SURGERY ROBOTS DOMINANCE Manual and Robotic Large inci
Slide 11: Limitations of Robotic Surgery Today
LIMITATIONS OF ROBOTIC SURGERY TODAY HIGH COST DIFFICULT TO USE LIMITED CAPABILITIES LOW UTILIZATION THESE LIMITATIONS RESULT IN ONLY Capital and service costs Steep learning curves and Ill-suited for many outpatient Large profile, limited portability, 3.2% >$2M investment device-specific training p
Slide 12: Our Solution
03 OUR SOLUTION VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL 12
Slide 13: Our Solution
VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 03 | OUR SOLUTION PRIVATE AND CONFIDENTIAL 13
Slide 14: The System
THE SYSTEM 3D SCREEN PROPRIETARY 9 1.5cm 360 SOFTWARE TROCAR SIZE EXISTING SINGLE DEGREES OF SINGLE DEGREES PORT ROBOTS SURGEON VICARIOUS SURGICAL FREEDOM PER ARM INCISION 1 VIEW ROBOT CONSOLE 5-10x 7 1.5CM 1 2.5CM LOWER YEARS CAPITAL COST 2 OF R&D 30+ 34” wide 28 PATIENT CART PATENTS ISSUED FITS TH
Slide 15: Less Invasive While Maximizing Capabilities
LESS INVASIVE WHILE MAXIMIZING CAPABILITIES INCISION MOTION REACH VISIBILITY MOBILITY ONE 1.5CM 1 TROCAR HUMAN EQUIVALENT ANYWHERE 2 EVERYWHERE 2 PORTABLE VIDEO LINK VIDEO LINK 2 robotic arms and 1 camera through 9 degrees of freedom per arm Unprecedented dexterity through Natural view in any and al
Slide 16: Size
SIZE Simple, portable, and capable—the Vicarious Surgical robot fits through a standard door and can fit into surgical facilities without construction buildout VICARIOUS SURGICAL ROBOTS LEGACY SURGICAL ROBOTS VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 03 | OUR SOLUTION PRIVATE AND CONFIDENT
Slide 17: 360° Reach and View
360° REACH AND VIEW The Vicarious Surgical robot can work anywhere in the abdomen through a 1.5cm1 incision The 9 decoupled actuators in each arm provide unprecedented dexterity inside of an ultra thin support tube LIMITED L ARGE WORKING WORKING AREA AREA LEGACY SINGLE VICARIOUS PORT ROBOTS SURGICAL
Slide 18: Sensing and Visualization
SENSING AND VISUALIZATION 3D DEPTH MAPPING FULL MOTION FORCE SENSING TR ACKING + FEEDBACK AT EVERY JOINT 4K HIGH FR AME WIDE FOV AUTOFOCUS R ATE TONE ADJUSTING HEAD MOUNTED LIGHTING DISPL AY 1 [1] WHILE CAPABLE OF HEAD MOUNTED DISPL AY CURRENTLY, MAY REQUIRE CLINICAL DATA FOR 03 | OUR SOLUTION PRIVA
Slide 19: Economics
ECONOMICS Advanced engineering enables sterile portion to be disposable with competitive cost structure • 3D printed and injection molded parts with polymer fiber cables • Decoupled actuators enable polymer cables and parts, lowering part costs vs traditional manufacturing over 5-10x1 • Enables ster
Slide 20: Market Research Features
MARKET RESEARCH 1| 360º REACH PROVIDES ACCESS TO ENTIRE ABDOMEN FEATURES 2| FULLY ARTICULATING JOINTS ALLOW FOR 9 DEGREES OF FREEDOM Surgeons and administrators reacted positively to the features that our surgical robot provides. Their favorite features are 3| REAL-TIME 4K 3D VISUALIZATION WITH uniq
Slide 21: Market Research Competitor Comparison
MARKET RESEARCH COMPETITOR COMPARISON 5 | Major Breakthrough VERY EASY SELL Independent blinded study with surgeons and 4.8 hospitals shows over 4 out of 5 score (very easy sell), well above competing solutions 4 | Important Advance STRONG SELLING POSITION COMPARED TO MANUAL MINIMALLY INVASIVE SURGE
Slide 22: FDA Designated Breakthrough Technology
FDA DESIGNATED BREAKTHROUGH TECHNOLOGY Our product is the only surgical robot to Agreement for clearance with receive a breakthrough designation from prioritized review3 the FDA indicating that they agree with our product’s potential for clinical benefit1 Hospital reimbursement may be higher for usi
Slide 23: Our Pathway to Commercialization
04 OUR PATHWAY TO COMMERCIALIZATION VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL 23
Slide 24: Expected Roadmap
EXPECTED ROADMAP V&V Cadaver Study Complete Summative Usability Testing/ Cadaver Simulated Use Complete First V1.0 Unit Built Verification & Validation Complete Beta 1 Beta 2 Verification & FDA 510(k) Submission for DEVELOPMENT AND REGULATORY Validation Start Ventral Hernia Repair Filing FDA Presubm
Slide 25: Regulatory Strategy
VENTRAL HERNIA REGULATORY Initial launch of core product offering focused STRATEGY on 360º access and visualization for Ventral Hernia repair Verification and 510(k) Our regulatory strategy enables expedited Validation Filing filing while reducing risk by adopting a phased and scalable approach 510(
Slide 26: Our Market, Our Potential
05 OUR MARKET, OUR POTENTIAL VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL 26
Slide 27: First Indication: Ventral Hernia
FIRST INDICATION: VENTRAL HERNIA MARKET SIZE 1 EXISTING MEDICARE OUR FUNDAMENTAL ADVANTAGE REIMBURSEMENTS CMS provides an “unfettered path to coverage, beginning as soon as the same day as FDA market authorization for breakthrough devices”2 0.9M 3.3M US VENTRAL OUTSIDE US MEDICARE REIMBURSEMENT FOR
Slide 28: Addressable Procedures
INITIAL ADDRESSABLE ~11.5M 39M MARKET GALLBLADDER ABDOMINAL PROCEDURES 4 PROCEDURES ADDRESSABLE BY (~2.3M US) VICARIOUS 7 ~7.0M ALL OTHER ADDRESSABLE PROCEDURES TOTAL INITIAL HERNIA 3 ADDRESSABLE MARKET $136B (~1.5M US} ~13.4M 6 GI PROCEDURES 5 ~4.1M (~2.8M US) ~2.7M VENTRAL HYSTERECTOMY 2 HERNIA 1
Slide 29: Financial Projections
REVENUES & GROSS MARGIN FINANCIAL 1,200 100 SERVICE AND DISPOSABLES REVENUE PROJECTIONS 1,000 80% 79% 80% 83 78% 80% SYSTEM REVENUE 800 66 GROSS MARGIN GROSS MARGIN % REVENUE $M 600 50 Significant revenue potential with modest adoption: $1bn in revenue by 2027 with under 400 33 1% adoption 200 16 Gr
Slide 30: Select Public References
SELECT PUBLIC REFERENCES ENTERPRISE EV/REVENUE EV/REVENUE REVENUE CAGR VALUE 2024E 2025E 1 2023E-2025E 1 HIGH GROWTH MED-TECH - 10.2x 10.4x 23.1% - 16.3x 13.5x 22.0% DISRUPTIVE HC TECHNOLOGIES OTHER SURGICAL ROBOTICS $92.0B 12.1x 11.1x 11.9% VICARIOUS SURGICAL $1.1B 8.4x IMPLIED MULTIPLE 3.1x IMPLIE
Slide 31: Transaction Overview
TRANSACTION OVERVIEW Vicarious is preparing to go public through a ($ IN MILLIONS EXCEPT FOR SHARE PRICE) PRO FORMA OWNERSHIP 2 business combination with D8 and is raising SOURCES $115 million1 through a PIPE to further support Vicarious Rollover Equity $1000 long-term development plans D8 Cash Held
Slide 32: Thank You
THANK YOU VICARIOUS SURGICAL 78 Fourth Avenue vicarioussurgical.com Waltham, MA, 02451 +1.617.868.1700 VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL